Flores Jean's scientific contributions

Publication (1)

Full-text available
Based on our extensive pre-clinical data that show that ischemia/reperfusion-induced Acute Kidney Injury (AKI), an essentially treatment resistant complication in patients, can be effectively treated by the administration of allogeneic Mesenchymal Stem Cells (MSC), an FDA approved, Phase I Clinical Trial (www.clinicaltrials.gov; NCT00733876) in pat...


... Limited attempts with contradictory results have resulted from the exploration of the safety and efficacy of MSCs in recovering renal function after post-cardiac surgery AKI. An exploratory phase I trial studied the safety and feasibility of infusing allogeneic BM-MSCs in patients with several underlying comorbidities at high risk of developing AKI after open-heart surgery (14,15). Outcomes from the first five patients showed that prevention infusion of MSCs was safe, averted postoperative decline in renal function, and decreased time of hospitalization and rates of readmission. ...